CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Similarly, leukemic CML CD34+ cells have elevated PRMT5 expression compared with normal bone marrow CD34+ cells, and PRMT5 inhibition only affects the self-renewal of leukemic CD34+ stem cells (Jin et al., 2016).